Current data indicate that 20-30% of all marrow transplant recipients will experience poor marrow function or frank marrow failure. With the exception of graft rejection, the mechanisms responsible for these complications have not been defined. The purpose of this project is to test the hypothesis that cytomegalovirus (CMV) and graft-versus-host reactions (GVHR) cause poor marrow function or graft failure by compromising the marrow microenvironment. This hypothesis is supported by clinical analyses associating neutropenia with both CMV and GVHR, and in vitro data indicating both can inhibit stromal function in long-term marrow cultures. The extent to which CMV and GVHR influence marrow function in outpatient population, the mechanisms involved, and why only a proportion of patients with CMV and GVHR are so affected, remains unknown. To address these issues, a prospective study will be conducted in Aim 1 to determine the frequency at which CMV can be detected in patient marrow, its association with GVHR and with marrow function. Since preliminary data suggest that CMV pathogenicity may be associated with genetic differences in CMV envelope glycoproteins, the virus detected in patient marrow will also be genotyped.
In Aims 2 and 3, different in vitro models will be used to define how specific strains of CMV, acting alone or in the presence of GVHR, influence stromal function. One model will utilize primary long-term marrow cultures from CMV seropositive normal donors to identify sites of viral latency and mechanisms of viral activation. The second model will use recently developed stromal cell lines to de fine the consequences of CMV infection in specific cell types, before and after exposure to CMV specific HLA restricted T cell clones. The information provided by these studies should increase our understanding of hematopoiesis in general, and improve our ability to accurately diagnose and treat poor marrow function in transplant recipients and other immune compromised patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA018221-23
Application #
6268991
Study Section
Project Start
1998-04-01
Project End
1999-03-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
23
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Mielcarek, Marco; Storer, Barry E; Boeckh, Michael et al. (2009) Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 113:2888-94
Tseng, Li-Hui; Storer, Barry; Petersdorf, Effie et al. (2009) IL10 and IL10 receptor gene variation and outcomes after unrelated and related hematopoietic cell transplantation. Transplantation 87:704-10
Bensinger, W I (2009) Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia 23:442-8
Bensinger, William (2008) Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 26:480-92
Storek, Jan (2008) Immunological reconstitution after hematopoietic cell transplantation - its relation to the contents of the graft. Expert Opin Biol Ther 8:583-97
Bensinger, William I (2007) Is there still a role for allogeneic stem-cell transplantation in multiple myeloma? Best Pract Res Clin Haematol 20:783-95
Carpenter, Paul A; Hoffmeister, Paul; Chesnut 3rd, Charles H et al. (2007) Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host disease. Biol Blood Marrow Transplant 13:683-90
Bensinger, William I (2007) Reduced intensity allogeneic stem cell transplantation in multiple myeloma. Front Biosci 12:4384-92
Zaucha, Renata E; Buckner, Dean C; Barnett, Todd et al. (2006) Modified total body irradiation as a planned second high-dose therapy with stem cell infusion for patients with bone-based malignancies. Int J Radiat Oncol Biol Phys 64:227-34
Alkindi, S; Deeg, J H; Flowers, M E D (2006) Recovery of normal autologous myelopoiesis after graft rejection following allogeneic bone marrow transplant for agnogenic myeloid metaplasia. Clin Lab Haematol 28:134-7

Showing the most recent 10 out of 692 publications